Cigarette Prices in Egypt Increase by EGP 2-3

Mar.28.2023

Egypt's Eastern Company increases average cigarette prices by EGP 2-3 per pack on March 25.

On March 25th, Egypt's state-owned Eastern Company announced a 2-3 Egyptian pound (equivalent to approximately 0.44-0.66 yuan) increase in the average price of each pack of cigarettes, cigars, and pipe tobacco.

Ten packs of Cleopatra cigarettes are currently selling for 15 Egyptian pounds (about 3.3 yuan), while a pack of Cleopatra King Size is priced at 23 Egyptian pounds (about 5 yuan). Viceroy and Pall Mall cigarettes are selling for 33 Egyptian pounds (about 7.3 yuan) per pack.

The prices of Cleopatra Soft Queen, Boston/Belmont, Cleopatra Box (in white, black, and color), Cleopatra Mondial Switch, and Matossian cigarettes have all increased to 24 Egyptian pounds (approximately 5 yuan) per pack.

This is the first price increase for the company in 2023, following two previous increases in September 2022 and March 2022.

According to reports, the state-owned Eastern Tobacco Company of Egypt was established in 1920 and is the largest tobacco producer in Egypt.

The revenue of Eastern Company increased by 6% in 2022, reaching 67.9 billion Egyptian pounds (approximately 15.1 billion Chinese yuan), higher than the 63.8 billion Egyptian pounds (approximately 4.2 billion Chinese yuan) of the fiscal year 2021.

In September of last year, a subsidiary of Philippine-based company PMI partnered with tobacco company UTC to begin producing cigarettes in the Egyptian market. This marked the end of decades-long monopoly on cigarette production by a single company.

Reference:

Local cigarette prices in Egypt have increased by EGP 2-3 per pack.

#Traditional tobacco #Asia #Market #China

This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

U.S. CBP and FDA Seize 165,000 Illicit E-Cigarette Products; Total Value Exceeds $1.47 Million

U.S. Customs and Border Protection (CBP) seized approximately 165,000 illicit vaping products—including 90,000 e-cigarette devices and 75,000 refill cartridges—valued at over $1.47 million (MSRP). Following a joint assessment with the U.S. Food and Drug Administration (FDA), the products were deemed “adulterated and misbranded” for lacking required premarket authorization and were seized in accordance with the Federal Food, Drug, and Cosmetic Act (FD&C Act). The shipments, which featured multipl

Sep.30 by 2FIRSTS.ai

Co-op Faces Backlash Over Vape Promotion Strategy Post-Cyberattack

The Guardian reports that UK retailer Co-op is ramping up vape promotions to recover sales lost after an April cyberattack. Internal documents cite a £1M weekly sales gap and 100,000 fewer transactions. Staff say the move contradicts Co-op’s “ethical retail” image, as the government prepares to ban vape ads under the Tobacco and Vapes Bill.

Oct.28 by 2FIRSTS.ai

1,200 Health Leaders Urge UK Parliament to Pass Tobacco and Vapes Bill Swiftly

Over 1,200 UK health leaders urged Parliament to pass the Tobacco and Vapes Bill quickly, calling it vital to protect future generations. The bill would ban tobacco sales to anyone born after Jan 1, 2009, and restrict vape packaging and flavours. Health groups warned delays risk undermining “gamechanging” public health reforms.

Oct.27 by 2FIRSTS.ai

ceshi1111

Trusted by industry leaders and innovators, ARAC brings unmatched expertise in Modules 5 & 6, including label and claim development, comprehension testing, human factors/usability, and clinical-behavioral research such as actual use and switching studies. These studies generate the robust, real-world evidence needed to evaluate whether products are “Appropriate for the Protection of Public Health” (APPH) -- including randomized experimental longitudinal, actual use, cohort st

Oct.21